SAN JOSE, Calif.–(BUSINESS WIRE)–Cotchett, Pitre & McCarthy announced today the beginning of the 90-day Notice Period during which Class Members can submit their claims in this landmark settlement. On July 17, 2026, Judge Noël Wise of the U.S. District Court for the Northern District of California granted preliminary approval of this $250,000,000 Settlement with Apple in this nationwide false advertising class action concerning “Apple Intelligence” on iPhones. Plaintiffs allege that Apple

NEW YORK CITY & NEW ORLEANS–(BUSINESS WIRE)–Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into BellRing Brands, Inc. (NYSE: BRBR) (“BellRing” or the “Company”). On August 4, 2025, the Company reported its fiscal 3Q 2025 financial results, disclosing a disappointing new 2025 sales outlook, stating “BellRing management has narrowed its fiscal year 2025 outlook f

ALZ-101

ALZ-101, Alzinova’s therapeutic vaccine candidate for Alzheimer’s disease.
ALZ-101, Alzinova’s therapeutic vaccine candidate for Alzheimer’s disease.

GOTHENBURG, Sweden, Sept. 21, 2026 (GLOBE NEWSWIRE) — As World Alzheimer’s Day highlights the continued unmet need in Alzheimer’s disease, Swedish clinical-stage biopharmaceutical company Alzinova AB (Nasdaq First North: ALZ) is advancing on two fronts: initiating the global Phase II start-up of its therapeutic vaccine ALZ-101 while advancing a blood-based diagnostic program based on the same proprietary technology.

The Phase II program follows a completed Phase Ib study in which ALZ-101 showed a favorable safety and tolerability profile and generated strong, long-lasting Aβ-specific immune responses. Exploratory analyses also showed stabilization of cognition and relevant biomarkers over two years, supporting the potential for slower disease progression versus historical controls. ALZ-101 has also received FDA Investigational New Drug (IND) clearance and Fast Track designation.

Together with Worldwide Clinical Trials, Alzinova has completed the Phase II study kick-off and commenced the operational start-up phase. Approximately 120 participants with early Alzheimer’s disease are planned for enrollment, with the first participant expected around the turn of 2026/2027.

At the same time, Alzinova is expanding the potential applications of its proprietary Aβ42CC technology into diagnostics. In collaboration with Amsterdam UMC, the company is developing a blood-based test to validate and build on findings from the Phase Ib study. Separately, Alzinova has signed a Letter of Intent with Fujirebio to explore the test’s potential development and global commercialization.

“Alzheimer’s research is entering a period where earlier diagnosis and new treatment approaches increasingly need to move forward together. Our technology allows us to address both. With ALZ-101 entering Phase II start-up and our diagnostic program advancing, we are entering an important new stage of development,” comments Tord Labuda, CEO of Alzinova.

To fund the next stage, Alzinova has launched a rights issue of approximately USD 5.5 million. The net proceeds are intended primarily to fund the initiation of the Phase II clinical study, related Chemistry, Manufacturing and Controls (CMC) activities and working capital.

For further information, please contact:
Tord Labuda, CEO
E-mail: info@alzinova.com
www.alzinova.com

About Alzinova AB
Alzinova AB is a Swedish clinical-stage biopharmaceutical company developing treatments for Alzheimer’s disease, with a focus on toxic amyloid-beta oligomers. Its lead candidate, ALZ-101, is a therapeutic vaccine. Alzinova’s patented AβCC peptide technology enables the development of disease-modifying treatments targeting toxic amyloid-beta oligomers central to disease onset and progression.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5ddb99c4-f530-49cb-9d51-60276f6765cb

NEW YORK CITY & NEW ORLEANS–(BUSINESS WIRE)–Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of MISTRAS Group, Inc. (NYSE: MG) to affiliates of H.I.G. Capital. Under the terms of the proposed transaction, shareholders of MISTRAS will receive $20.35 in cash for each share of MISTRAS that they own. KSF is seeking to determine whether this consideration and the process that led to it are ade

Regulated information
Nazareth (Belgium)/Rotterdam (The Netherlands), 21 March 2026 – 7PM CET

Fagron increases share capital through exercise subscription rights

Fagron announces that as a result of the exercise of subscription rights, 43,920 new shares have been issued on 21 September 2026.

In accordance with the Belgian transparency legislation, Fagron notes that its total share capital currently amounts to € 507,764,714.08. The total number of shares with voting rights after the issue amounts to 73,817,024 which is also the total number of voting rights (the ‘denominator’). The total number of subscription rights (formerly known as warrants) to subscribe to not yet issued shares with voting rights amounts to 962,713.

Further information
Ignacio Artola
Global Head of Investor Relations
Tel. +34 670385795
ignacio.artola@fagron.com

About Fagron

Fagron is the leading global company active in pharmaceutical compounding, focusing on delivering personalized medicine to hospitals, pharmacies, clinics, and patients in more than 38 countries around the world.

The Belgian company Fagron NV is based in Nazareth and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol ‘FAGR’. Fagron’s operational activities are managed through the Dutch company Fagron BV with head office in Rotterdam.

Important information regarding forward-looking statements

Certain statements in this press release may be deemed to be forward-looking. Such forward-looking statements are based on current expectations and are influenced by various risks and uncertainties. Consequently, Fagron cannot provide any guarantee that such forward-looking statements will, in fact, materialize and cannot accept any obligation to update or revise any forward-looking statement as a result of new information, future events or for any other reason.

In the event of differences between the English translation and the Dutch original of this press release, the latter prevails.

Attachment

NEW YORK–(BUSINESS WIRE)–Why: Rosen Law Firm, a global investor rights law firm, reminds investors about a class action lawsuit on behalf of purchasers of common stock of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) between February 28, 2024 and February 25, 2026, inclusive (the “Class Period”). PROCEPT is a medical technology company.For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653.The Allegations: Rosen Law Firm is Investigating the Allegat

ATLANTA, Sept. 21, 2026 (GLOBE NEWSWIRE) — The Ohio Valley Conference has renewed its partnership with Gray Media to broadcast OVC athletic events across twenty Gray markets in eight states after a successful set of broadcasts a year ago.

As part of the Conference’s multi-year contract with ESPN, the entire package will also be simulcast live nationally on ESPN+ and available through the ESPN app without digital blackouts.

The 2026-27 package again features select men’s and women’s basketball matchups, plus expanded coverage with three men’s soccer, three women’s soccer and four volleyball contests this fall.   A list of basketball contests to broadcast on Gray stations will be announced at a later date, in addition to plans for spring sports coverage.

Gray’s Tennessee Valley Sports & Entertainment Network and Mid-South Sports & Entertainment Network each looks forward to bringing two Tennessee institutions – Tennessee State University and the University of Tennessee at Martin – to viewers across the state. The Tennessee Valley Sports & Entertainment Network broadcasts over-the-air in Nashville, Knoxville, and Chattanooga, while the Mid-South Sports & Entertainment Network broadcasts in Memphis and Jackson.   The OVC is headquartered in Brentwood, Tennessee (just south of Nashville).

In addition, Gray’s Matrix Midwest in St. Louis and Cape Girardeau, Missouri, will serve hometown viewers of OVC’s Southeast Missouri State University, Southern Illinois University Edwardsville and Lindenwood University, while Gray’s Illinois stations in Champaign, Peoria, Quincy, and Rockford are excited to serve fans of OVC’s Western Illinois University and Eastern Illinois University. Gray’s Indiana stations in Evansville, Ft. Wayne, South Bend, Lafayette and Terre Haute will focus on the University of Southern Indiana, and Gray will also bring the package to fans of Morehead State University in Lexington, Kentucky.

The tentative schedule of available games is below. Not all markets will carry all games. Check local listings for times and channels.

• Friday, Sept. 25: Southern Indiana at Eastern Illinois, 6:00 p.m. CT (Volleyball)
• Sunday, Sept. 27: UT Martin at Southern Indiana, 1:00 p.m. CT (Women’s Soccer)
• Sunday, Oct. 4: Southern Indiana at Western Illinois, 1:00 p.m. CT (Men’s Soccer)
• Sunday, Oct. 11: Morehead State at Southeast Missouri, 1:00 p.m. CT (Women’s
Soccer)
• Sunday, Oct. 18: Lindenwood at Southern Indiana, 3:00 p.m. CT (Men’s Soccer)
• Friday, Oct 23: Southeast Missouri at UT Martin, 6:00 p.m. CT (Volleyball)
• Sunday, Oct. 25: SIUE at Lindenwood, 1:00 p.m. CT (Women’s Soccer)
• Sunday, Nov. 1: Eastern Illinois at SIUE, 1:00 p.m. CT (Men’s Soccer)
• Friday, Nov. 6: Southern Indiana at Tennessee State, 6:00 p.m. CT (Volleyball)
• Friday, Nov. 13: Western Illinois at Morehead State, 5:00 p.m. ET (Volleyball)

The Ohio Valley Conference was founded in 1948, making it the eighth-oldest Division I athletic conference. Over the years OVC teams have garnered national championships in football along with national team or individual titles in the sports of rifle, cross country, track and golf.  In the 1950s the OVC became a pioneer when Morehead State became one of the first non-traditionally Black mid-southern institutions to accept an African American student. Soon after the passing of Title IX legislation, the OVC began formulating plans for women’s athletics, which began in 1977. The OVC has long been a national leader in sportsmanship and in 1995 implemented a first-of-its-kind Sportsmanship Statement, a policy that promotes principles of fair play, ethical conduct and respect for one’s opponent.
 
The Ohio Valley Conference sponsors 19 championship sports. The league consists of nine member institutions in five states, including Eastern Illinois University, Lindenwood University, Morehead State University, Southeast Missouri State University, Southern Illinois University Edwardsville, University of Southern Indiana, Tennessee State University, the University of Tennessee at Martin and Western Illinois University.

About Gray Media:

Gray Media, Inc. (NYSE: GTN) is a multimedia company headquartered in Atlanta, Georgia. We are the nation’s largest owner of top-rated local television stations and digital assets. We serve 117 full-power television markets that collectively reach approximately 37% of US television households. The portfolio includes 78 markets with the top-rated television station and 101 markets with the first and/or second highest rated television station in average all-day ratings across the 116 of such markets that were measured by Nielsen in 2025. We also own the largest Telemundo Affiliate group with 46 markets and Gray Digital Media, a full-service digital agency offering national and local clients digital marketing strategies with the most advanced digital products and services. Our additional media properties include video production companies Raycom Sports, Tupelo Media Group, and PowerNation Studios, and studio production facilities Assembly Atlanta and Third Rail Studios.

Gray Contact:

Sandy Breland, Executive Vice President, Chief Operating Officer, 404-266-8333

#         #        #

LYON, France–(BUSINESS WIRE)–Regulatory News: MaaT Pharma (EURONEXT : MAAT – la « Société »), société de biotechnologies en stade clinique avancé, leader dans le développement de Microbiome Ecosystem TherapiesTM (MET) visant à améliorer la survie des patients atteints de cancer grâce à la modulation du système immunitaire, annonce aujourd’hui les prochaines étapes du développement clinique de MaaT034, premier écosystème microbien co-cultivé et sélectionné sur la base de ses fonctions, issu de

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.